Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab in Patients With HER2 Positive Operable Breast Cancer

NCT00532857 is registered in ClinicalTrials.gov with Jungsil Ro as lead sponsor.

NCT NCT00532857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00532857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab in Patients With HER2 Positive Operable Breast Cancer
Lead sponsor
Jungsil Ro
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2007
Completion date
September 30, 2011
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer